Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2445${count})

  • Community Fast Track, 2005
    Specific Inhibition of Nucleation of Alpha-synuclein Aggregation as a Therapeutic Strategy

    There is considerable evidence that aggregates of the human brain protein alpha-synuclein are a primary cause of the loss of neurons in Parkinson's disease.  We have tried to find out what initiates...

  • Community Fast Track, 2005
    Use of NR2D-selective NMDA Receptor Modulators in the Treatment of PD

    The frontline pharmacological treatment for Parkinson’s disease is associated with serious side effects, creating a need for new therapeutic strategies.  Recent evidence suggests that selective...

  • Target Validation, 2005
    Testing of small molecules in an alpha-synuclein pre-clinical model of Parkinson’s disease

    Although Parkinson’s disease is mainly sporadic, at least six genes have been recently linked to familial PD. It is believed that a molecular understanding of the consequences of these gene mutations...

  • Target Validation, 2005
    In vivo Target Validation: RNA Interference to Silence Alpha-Synuclein in Parkinson’s Disease Pre-clinical Models

    Recent studies have shown that a protein known as alpha-synuclein plays a central role in the development of Parkinson’s disease. While its normal function in the brain remains unknown, the...

  • Target Validation, 2005
    Metabotropic glutamate receptors in L-DOPA-induced dyskinesia

    Levodopa-induced dyskinesia in Parkinson’s disease is thought to depend on an overactive stimulation of brain glutamate receptors. This project aims to evaluate a particular class of glutamate...

  • Target Validation, 2005
    Discovery of Allosteric Potentiators of mGluR7 as Novel Antiparkinsonian Agents

    Exciting advances over recent years have identified specific pathways in the brain that become overactive in patients with Parkinson’s disease. The primary pathology of Parkinson’s disease involves...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.